secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2026-06-03T11:34:29+00:00
Accession:  0001437749-26-019262
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics reports positive Phase 1 data for subcutaneous BRIUMVI; bioavailability >60% vs IV
--------------------------------------------------------------------------------

- Mean bioavailability >60% relative to IV; lower bound of 95% CI >55%.
- PK modeling predicts non-inferior total drug exposure for quarterly SC dosing (GMR 1.21, lower 90% CI 1.15).
- Subcutaneous BRIUMVI well tolerated; injection-site reactions <5%, no new safety signals.
- B-cell depletion with SC consistent with IV; supports biologic activity.
- Phase 3 fully enrolled; top-line data expected late 2026 or early 2027; potential approval in 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926019262/0001437749-26-019262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926019262/tgtx20260602_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-019262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer